› $150,000,000 verdict in personal injury case
Using antidepressant known as selective serotonin reuptake inhibitors, or SSRIs, during pregnancy can increase the risk of various birth defects, whether the drugs are used early or late in pregnancy, according to two studies published in the past six months.
A new study, published in the January 12 issue of the British Medical Journal, adds more evidence that antidepressants known as selective serotonin reuptake inhibitors, or SSRIs, when used during pregnancy, can increase the chances that the newborn will have a life-threatening lung defect known as persistent pulmonary hypertension (PPHN).
One in five adults in the United States suffered from mental illness last year, and women were far more likely than men to have been diagnosed with mental, behavioral or emotional disorders, according to a newly released government study.
The risk of a fetus developing a rare but life threatening lung defect is relatively low. But if a mother takes a common class of antidepressant medication late in her pregnancy, the risk for her baby to develop the condition doubles, according to a Swedish study.
The Food and Drug Administration (FDA) is giving health care professionals the green light to continue prescribing a class of antidepressants to pregnant women despite a 2006 warning that the drugs may cause newborns to be born with persistent pulmonary hypertension (PPHN). The agency’s earlier warning was based on a study that showed an increased risk for fetuses to develop the condition if they were exposed to selective serotonin reuptake inhibitors (SSRIs) after 20 weeks gestation. Since then, the agency says there have been conflicting studies evaluating this risk, making it unclear just how dangerous SSRIs are to developing fetuses.
Scientists are currently debating whether there is a link between a class of antidepressants known as selective serotonin reuptake inhibitors (SSRI) and the risk of suicidal ideation and behavior, a problem identified shortly after the highly prescribed drugs hit the market.
New studies suggest use of antidepressants during pregnancy may contribute to an increased risk of heart defects in newborns, but the Food and Drug Administration (FDA) says it is too soon to issue any specific warnings about that risk.
About $1 billion has been paid out by drug maker GlaxoSmithKline to resolve “failure to warn” lawsuits over its popular antidepressant Paxil. The lawsuits include cases of birth defects, suicides, and addiction allegedly caused by the medication.
Pregnant women who take certain types of antidepressants are at greater risk for preterm delivery or other birth complications, according to a study published in the American Journal of Obstetrics & Gynecology. The findings add more fuel to the argument that antidepressants not be prescribed to pregnant women and women of childbearing age unless absolutely necessary.
According to a recent study, nearly 75 percent of all antidepressants were prescribed to patients without documented psychiatric conditions by non-psychiatrists in 2007, raising a host of concerns including the potential for patients to suffer serious side effects from the drugs that could put their unborn children at risk.
